Search

Displaying results 5601 - 5610 of 9670 in total
  1. Drug

    QR-313

    go.drugbank.com/drugs/DB17867
    Investigational

    It is being investigated for the treatment of dystrophic epidermolysis bullosa.[A259867]

  2. Drug

    Onvitrelin ucalontide

    go.drugbank.com/drugs/DB19183
    Investigational

    Onvitrelin ucalontide is under investigation in clinical trial NCT01485848 (EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer).

    Synonyms: Ep-100 (peptide), Membrane-disrupting peptide ep-100
  3. Drug

    Fludeoxyglucose

    go.drugbank.com/drugs/DB15107
    Investigational

    Fludeoxyglucose is under investigation in clinical trial NCT03262389 (Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma).

  4. Drug

    KB002

    go.drugbank.com/drugs/DB05194
    Experimental

    It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.

  5. Drug

    Carphenazine

    go.drugbank.com/drugs/DB01038
    ApprovedWithdrawn

    Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.

  6. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients. … AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).

  7. Drug

    Iclaprim

    go.drugbank.com/drugs/DB06358
    Investigational

  8. Drug

    Edonerpic

    go.drugbank.com/drugs/DB05938
    Investigational

    Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

  9. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54146] Zemcelpro was granted conditional marketing authorization in the European Union in August 2025 for use in allogeneic hematopoietic stem cell transplantation following myeloablative conditioning

  10. Drug

    BMS-690514

    go.drugbank.com/drugs/DB11665
    Investigational

    BMS-690514 has been investigated for the treatment of Breast Cancer.